The cost-effectiveness of natalizumab in patients with relapsing multiple sclerosis

被引：0
|
作者：
Meyer, K. [1 ]
Chiao, E. [1 ]
机构：
[1] Xcenda, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)68808-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A89 / A89
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal
    Pinheiro, Bernardete
    Guerreiro, Rita
    Costa, Joao
    Miguel, Luis Silva
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 484 - 491
  • [42] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [43] COST-EFFECTIVENESS ANA LYSES OF NATALIZUMAB FOR 2ND LINE VERSUS GLATIRAMER ACETATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS IN BRAZIL
    Nishikawa, A. M.
    Paladini, L.
    Liamas, A. L.
    Bueno, C. C.
    Clark, O. A. C.
    VALUE IN HEALTH, 2013, 16 (07) : A721 - A721
  • [44] Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
    Sorensen, Per Soelberg
    Jensen, Poul Erik Hyldgaard
    Haghikia, Aiden
    Lundkvist, Malin
    Vedeler, Christian
    Sellebjerg, Finn
    Koch-Henriksen, Nils
    Fogdell-Hahn, Anna
    Myhr, Kjell-Morten
    Hillert, Jan
    Gold, Ralf
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (09) : 1074 - 1078
  • [45] Natalizumab for relapsing remitting multiple sclerosis
    Pucci, Eugenio
    Giuliani, Giorgio
    Solari, Alessandra
    Simi, Silvana
    Minozzi, Silvia
    Di Pietrantonj, Carlo
    Galea, Ian
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (10):
  • [46] Natalizumab (Tysabri) for relapsing multiple sclerosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2005, 47 (1202): : 13 - 15
  • [47] Natalizumab for relapsing multiple sclerosis - Reply
    Miller, DH
    O'Connor, PW
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (16): : 1598 - 1599
  • [48] Natalizumab for Relapsing Remitting Multiple Sclerosis
    Pucci, Eugenio
    Giuliani, Giorgio
    Solari, Alessandra
    Simi, Silvana
    Minozzi, Silvia
    Di Pietrantonj, Carlo
    Galea, Ian
    BAHRAIN MEDICAL BULLETIN, 2011, 33 (04)
  • [49] Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
    Sharmin, S.
    Lefort, M.
    Andersen, J.
    Horakova, D.
    Havrdova, E. K.
    Alroughani, R.
    Izquierdo, G.
    Eichau, S.
    Ozakbas, S.
    Butzkueven, H.
    Patti, F.
    Onofrj, M.
    Lugaresi, A.
    Terzi, M.
    Grammond, P.
    Grand'Maison, F.
    Yamout, B.
    Prat, A.
    Girard, M.
    Duquette, P.
    Boz, C.
    Trojano, M.
    McCombe, P.
    Slee, M.
    Lechner-Scott, J.
    Turkoglu, R.
    Sola, P.
    Ferraro, D.
    Granella, F.
    Shaygannejad, V.
    Prevost, J.
    Skibina, O.
    Solaro, C.
    Karabudak, R.
    Van Wijmeersch, B.
    Csepany, T.
    Spitaleri, D.
    Vucic, S.
    Leray, E.
    Sorensen, P. S.
    Sellebjerg, F.
    Magyari, M.
    Vukusic, S.
    Kalincik, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 786 - 788
  • [50] Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile
    Ysrraelit, Maria Celica
    Caride, Alejandro
    Sinay, Vladimiro
    Rivera Kindel, Mario
    Halfon, Mario Javier
    Patrucco, Liliana
    Piedrabuena, Raul
    Diaz Aragunde, Vanina Eleonor
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2021, 79 (05) : 407 - 414
12345